Assessment of thrombin-activatable fibrinolysis inhibitor levels in essential hypertension

Ayla Yıldız; Kerem Okutur; Nezaket Eren

Makale detayları

Assessment of thrombin-activatable fibrinolysis inhibitor levels in essential hypertension

Yazarlar:

Ayla Yıldız | Kerem Okutur | Nezaket Eren

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Internal Diseases | Medical Biochemistry - Proteins | Peptides and Proteomics

Dergi:

The European Research Journal Vol.11 Issue 1, pp.1-10

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001335632

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: Most research in this field has highlighted the significance of the fibrinolytic system in essential hypertension, revealing anomalies within the coagulation and fibrinolytic pathways that contribute to a hypercoagulable condition. We aim to investigate thrombin-activatable fibrinolysis inhibitor TAFI levels in individuals diagnosed with high blood pressure. Methods: We compared 40 newly diagnosed cases of essential hypertension, who were not receiving antihypertensive medication, with 40 normotensive individuals as controls. Various parameters and TAFI levels were assessed in all subjects and compared between the groups. Additionally, hypertensive patients were classified based on whether they exhibited high or normal cholesterol levels 200 mgdL. Results: The concentrations of TAFI were significantly higher in the hypertensive cohort compared to the normotensive counterparts 116.9529.76 and 77.7232.78 ngmL , respectively; P0.001. In addition, the high blood pressure cohort exhibited a notably higher mean body mass index BMI in contrast to the normotensive group 29.554.82 vs. 24.933.07 kgm2, respectively; P0.001. On the other hand, the remaining results showed no statistically significant differences between the two cohorts. Linear regression analysis revealed that blood pressure status and BMI independently correlated with plasma TAFI levels. Conclusions: The concentrations of TAFI are elevated in patients with high blood pressure compared to individuals with normal blood pressure, irrespective of high cholesterol levels. Further exploration is necessary to clarify the involvement of TAFIs in the pathophysiology of primary hypertension, necessitating advanced investigatory initiatives.

 Objectives: Most research in this field has highlighted the significance of the fibrinolytic system in essential hypertension, revealing anomalies within the coagulation and fibrinolytic pathways that contribute to a hypercoagulable condition. We aim to investigate thrombin-activatable fibrinolysis inhibitor TAFI levels in individuals diagnosed with high blood pressure. Methods: We compared 40 newly diagnosed cases of essential hypertension, who were not receiving antihypertensive medication, with 40 normotensive individuals as controls. Various parameters and TAFI levels were assessed in all subjects and compared between the groups. Additionally, hypertensive patients were classified based on whether they exhibited high or normal cholesterol levels 200 mgdL. Results: The concentrations of TAFI were significantly higher in the hypertensive cohort compared to the normotensive counterparts 116.9529.76 and 77.7232.78 ngmL , respectively; P0.001. In addition, the high blood pressure cohort exhibited a notably higher mean body mass index BMI in contrast to the normotensive group 29.554.82 vs. 24.933.07 kgm2, respectively; P0.001. On the other hand, the remaining results showed no statistically significant differences between the two cohorts. Linear regression analysis revealed that blood pressure status and BMI independently correlated with plasma TAFI levels. Conclusions: The concentrations of TAFI are elevated in patients with high blood pressure compared to individuals with normal blood pressure, irrespective of high cholesterol levels. Further exploration is necessary to clarify the involvement of TAFIs in the pathophysiology of primary hypertension, necessitating advanced investigatory initiatives.

 Objectives: Most research in this field has highlighted the significance of the fibrinolytic system in essential hypertension, revealing anomalies within the coagulation and fibrinolytic pathways that contribute to a hypercoagulable condition. We aim to investigate thrombin-activatable fibrinolysis inhibitor TAFI levels in individuals diagnosed with high blood pressure. Methods: We compared 40 newly diagnosed cases of essential hypertension, who were not receiving antihypertensive medication, with 40 normotensive individuals as controls. Various parameters and TAFI levels were assessed in all subjects and compared between the groups. Additionally, hypertensive patients were classified based on whether they exhibited high or normal cholesterol levels 200 mgdL. Results: The concentrations of TAFI were significantly higher in the hypertensive cohort compared to the normotensive counterparts 116.9529.76 and 77.7232.78 ngmL , respectively; P0.001. In addition, the high blood pressure cohort exhibited a notably higher mean body mass index BMI in contrast to the normotensive group 29.554.82 vs. 24.933.07 kgm2, respectively; P0.001. On the other hand, the remaining results showed no statistically significant differences between the two cohorts. Linear regression analysis revealed that blood pressure status and BMI independently correlated with plasma TAFI levels. Conclusions: The concentrations of TAFI are elevated in patients with high blood pressure compared to individuals with normal blood pressure, irrespective of high cholesterol levels. Further exploration is necessary to clarify the involvement of TAFIs in the pathophysiology of primary hypertension, necessitating advanced investigatory initiatives.

 Objectives: Most research in this field has highlighted the significance of the fibrinolytic system in essential hypertension, revealing anomalies within the coagulation and fibrinolytic pathways that contribute to a hypercoagulable condition. We aim to investigate thrombin-activatable fibrinolysis inhibitor TAFI levels in individuals diagnosed with high blood pressure. Methods: We compared 40 newly diagnosed cases of essential hypertension, who were not receiving antihypertensive medication, with 40 normotensive individuals as controls. Various parameters and TAFI levels were assessed in all subjects and compared between the groups. Additionally, hypertensive patients were classified based on whether they exhibited high or normal cholesterol levels 200 mgdL. Results: The concentrations of TAFI were significantly higher in the hypertensive cohort compared to the normotensive counterparts 116.9529.76 and 77.7232.78 ngmL , respectively; P0.001. In addition, the high blood pressure cohort exhibited a notably higher mean body mass index BMI in contrast to the normotensive group 29.554.82 vs. 24.933.07 kgm2, respectively; P0.001. On the other hand, the remaining results showed no statistically significant differences between the two cohorts. Linear regression analysis revealed that blood pressure status and BMI independently correlated with plasma TAFI levels. Conclusions: The concentrations of TAFI are elevated in patients with high blood pressure compared to individuals with normal blood pressure, irrespective of high cholesterol levels. Further exploration is necessary to clarify the involvement of TAFIs in the pathophysiology of primary hypertension, necessitating advanced investigatory initiatives.

Makale detayları

Assessment of thrombin-activatable fibrinolysis inhibitor levels in essential hypertension

Yazarlar:

Ayla Yıldız | Kerem Okutur | Nezaket Eren

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Internal Diseases | Medical Biochemistry - Proteins | Peptides and Proteomics

Dergi:

The European Research Journal Vol.11 Issue 1, pp.1-10

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001335632

pISSN:

2149-3189

Thrombin activatable fibrinolysis inhibitor

cardiovascular diseases

thrombosis

fibrinolysis

Sayı

Makale detayları

Assessment of thrombin-activatable fibrinolysis inhibitor levels in essential hypertension

Yazarlar: Ayla Yıldız | Kerem Okutur | Nezaket Eren

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Internal Diseases | Medical Biochemistry - Proteins | Peptides and Proteomics

Dergi: The European Research Journal Vol.11 Issue 1, pp.1-10

Belge Tipi: Makale

Yayın Tarihi: 4/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001335632

pISSN: 2149-3189

Thrombin activatable fibrinolysis inhibitor

cardiovascular diseases

thrombosis

fibrinolysis

Sayı

Yazarlar:

Ayla Yıldız | Kerem Okutur | Nezaket Eren

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Internal Diseases | Medical Biochemistry - Proteins | Peptides and Proteomics

Dergi:

The European Research Journal Vol.11 Issue 1, pp.1-10

Belge Tipi:

Makale

Yayın Tarihi:

4/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001335632

pISSN:

2149-3189